Alnylam Pharmaceuticals (ALNY)
scored another big win Thursday morning, with the company's detailed
presentation of clinical data on patisiran showing strong efficacy and
safety relative to future competitor Ionis's (IONS)
data on inotersen in patients with hereditary ATTR amyloidosis with
polyneuropathy (also called familial amyloid polyneuropathy, or FAP).
Alnylam's
data were quite good, but not a knock-out blow against Ionis's
inotersen, as you can expect Ionis to build its marketing message around
an easier and more tolerable administration and perhaps compete on
price. Still, for Alnylam, this head-to-head competition went about as
well as could be expected and should raise the hopes of getting an
advantageous label from the FDA.
Read the full article here:
Alnylam Pharmaceuticals Wins Another Round
No comments:
Post a Comment